Table 1.
Percent increase in proliferation in response to ligand
| Ligand conc., ng/ml | U87MG (parental)
|
U87/T691-1
|
||
|---|---|---|---|---|
| EGF | PDGF-BB | EGF | PDGF-BB | |
| 0 | — | — | — | — |
| 0.01 | 18.5 ± 0.6 | 35.8 ± 6.1 | 6.5 ± 5.1 | 30.0 ± 5.6 |
| 0.1 | 53.3 ± 3.9 | 47.3 ± 9.2 | 6.8 ± 4.5 | 40.8 ± 4.8 |
| 1.0 | 58.6 ± 4.9 | 43.5 ± 5.1 | 8.8 ± 4.5 | 47.1 ± 7.4 |
| 10.0 | 64.5 ± 7.8 | 43.5 ± 6.9 | 3.7 ± 2.2 | 45.9 ± 3.9 |
| 100 | 61.1 ± 6.2 | 59.9 ± 9.3 | 9.0 ± 5.4 | 53.2 ± 12.7 |
Proliferation in response to either EGF or PDGF-BB is shown between the U87MG cells and the U87/T691-1 cell line (expressing the T691stop truncated form of Neu). These data represent a compilation of six independent experiments (the response of U87/T691-1 to EGF represents data from eight separate experiments). Proliferation in response to ligand was determined by the incorporation of MTT under conditions described in Materials and Methods. The mean % increase above baseline (no ligand) ± SEM is shown. The measured proliferation was determined to be over a linear range for this cell line. conc., concentration.